The scientist’s investigation covers issues in Internal medicine, Renal function, Endocrinology, Albuminuria and Kidney disease. His Renal function study which covers Autosomal dominant polycystic kidney disease that intersects with Tolvaptan and Polycystic kidney disease. His work deals with themes such as Gastroenterology, Placebo, Nephrology and Urology, which intersect with Endocrinology.
His Albuminuria study combines topics in areas such as Acute kidney injury and Urinary system. His Kidney disease research is multidisciplinary, relying on both Cystatin C, Genome-wide association study, Pathology, Intensive care medicine and End stage renal disease. In his study, which falls under the umbrella issue of Risk factor, Years of potential life lost and Environmental health is strongly linked to Relative risk.
Ron T. Gansevoort mostly deals with Internal medicine, Renal function, Endocrinology, Kidney disease and Albuminuria. His Internal medicine study combines topics from a wide range of disciplines, such as Diabetes mellitus and Cardiology. The various areas that Ron T. Gansevoort examines in his Renal function study include Urology, Disease, Creatinine, Kidney and Cohort.
His Endocrinology research incorporates elements of Gastroenterology and Prospective cohort study. He has researched Kidney disease in several fields, including Nephrology, Cystatin C, Intensive care medicine and End stage renal disease, Hemodialysis. Ron T. Gansevoort combines subjects such as Proteinuria, Surgery, Nephropathy and Diabetic nephropathy with his study of Albuminuria.
His primary areas of study are Internal medicine, Renal function, Kidney disease, Autosomal dominant polycystic kidney disease and Urology. His Internal medicine research includes elements of Gastroenterology, Diabetes mellitus, Endocrinology and Cardiology. The concepts of his Renal function study are interwoven with issues in Acute kidney injury, Proportional hazards model, Creatinine, Kidney and Type 2 diabetes.
His biological study focuses on Albuminuria. His studies deal with areas such as Tolvaptan, Copeptin and Polycystic kidney disease as well as Autosomal dominant polycystic kidney disease. His Urology research is multidisciplinary, incorporating perspectives in Adverse effect, Urinary system, Urine and Muscle mass.
Internal medicine, Renal function, Kidney disease, Albuminuria and Hazard ratio are his primary areas of study. His study in Gastroenterology extends to Internal medicine with its themes. He interconnects Body mass index, Urology, Diabetes mellitus, Urine and Kidney in the investigation of issues within Renal function.
His biological study spans a wide range of topics, including Nephrology, MEDLINE, Intensive care medicine, Clinical endpoint and Disease. Ron T. Gansevoort has included themes like Diabetes mellitus genetics, Gene knockdown, Bioinformatics, Medical genetics and Regulation of gene expression in his Albuminuria study. Ron T. Gansevoort works mostly in the field of Hazard ratio, limiting it down to topics relating to Cohort and, in certain cases, Cohort study, Relative risk, Confidence interval, C-reactive protein and Proportional hazards model, as a part of the same area of interest.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
Mohammad H Forouzanfar;Lily Alexander;H Ross Anderson;Victoria F Bachman.
The Lancet (2015)
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.
Kunihiro Matsushita;Marije van der Velde;Brad C. Astor;Mark Woodward.
The Lancet (2010)
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013 : a systematic analysis for the Global Burden of Disease Study 2013
Mohammad H. Forouzanfar;Lily Alexander;H. Ross Anderson;Victoria F. Bachman.
The Lancet (2015)
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
Andrew S. Levey;Paul E. de Jong;Josef Coresh;Meguid E.l. Nahas.
Kidney International (2011)
Defining the role of common variation in the genomic and biological architecture of adult human height
Andrew R. Wood;Tonu Esko;Jian Yang;Sailaja Vedantam.
Nature Genetics (2014)
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.
Ron T Gansevoort;Ricardo Correa-Rotter;Brenda R Hemmelgarn;Tazeen H Jafar.
The Lancet (2013)
Genetic studies of body mass index yield new insights for obesity biology
Adam E. Locke;Bratati Kahali;Sonja I. Berndt;Anne E. Justice.
Faculty of Health; Institute of Health and Biomedical Innovation (2015)
Tolvaptan in patients with autosomal dominant polycystic kidney disease
Vicente E. Torres;Arlene B. Chapman;Olivier Devuyst;Olivier Devuyst;Ron T. Gansevoort.
The New England Journal of Medicine (2012)
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate.
Kunihiro Matsushita;Bakhtawar K. Mahmoodi;Bakhtawar K. Mahmoodi;Mark Woodward;Jonathan R. Emberson.
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality.: A collaborative meta-analysis of high-risk population cohorts
Marije van der Velde;Kunihiro Matsushita;Josef Coresh;Brad C. Astor.
Kidney International (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: